Ministry of Health Approves BrainStorm Cell Therapeutics Inc.’s NurOwn™ for the First Clinical Trial of Adult Stem Cell Therapy for ALS

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, and Hadasit, the technology transfer company of the Hadassah Medical Organization, announced today that Israel's Ministry of Health (MOH) has approved the Phase I/II clinical trial of NurOwn™, BrainStorm’s autologous stem cell therapy for people with amyotrophic lateral sclerosis (often referred to as ALS or Lou Gehrig's Disease). BrainStorm is the first company to receive approval from the MOH for a differentiated stem cell-based therapy.